ARGI Investment Services LLC Trims Holdings in Gilead Sciences, Inc. (GILD)

ARGI Investment Services LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,466 shares of the biopharmaceutical company’s stock after selling 639 shares during the quarter. ARGI Investment Services LLC’s holdings in Gilead Sciences were worth $953,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. ARGA Investment Management LP lifted its stake in Gilead Sciences by 17.4% in the second quarter. ARGA Investment Management LP now owns 44,029 shares of the biopharmaceutical company’s stock valued at $3,116,000 after buying an additional 6,530 shares during the last quarter. Micawber Capital LLC lifted its stake in Gilead Sciences by 14.3% in the second quarter. Micawber Capital LLC now owns 26,256 shares of the biopharmaceutical company’s stock valued at $1,858,000 after buying an additional 3,282 shares during the last quarter. Wesbanco Bank Inc. lifted its stake in Gilead Sciences by 0.4% in the second quarter. Wesbanco Bank Inc. now owns 28,654 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 125 shares during the last quarter. Atwood & Palmer Inc. lifted its stake in Gilead Sciences by 1.5% in the second quarter. Atwood & Palmer Inc. now owns 229,542 shares of the biopharmaceutical company’s stock valued at $16,247,000 after buying an additional 3,442 shares during the last quarter. Finally, Eii Capital Management Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $2,463,000. Institutional investors own 74.38% of the company’s stock.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock worth $36,269,486 in the last three months. 1.30% of the stock is owned by corporate insiders.

A number of equities research analysts have weighed in on the company. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $85.68.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.46 on Monday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The firm has a market capitalization of $96,012.22, a price-to-earnings ratio of 7.67, a P/E/G ratio of -1.23 and a beta of 1.13. The company has a current ratio of 4.86, a quick ratio of 4.74 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.75 earnings per share. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.83%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.

ILLEGAL ACTIVITY WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/06/argi-investment-services-llc-trims-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit